Roche reports Phase II data for lung cancer candidate

Roche (SIX:ROG; OTCQX:RHHBY) reported preliminary data from the Phase II OAM4558g trial of MetMab for second- and third-line treatment of metastatic non-small cell lung cancer (NSCLC). The monovalent mAb against c-Met every three weeks plus Tarceva erlotinib improved median progression-free survival (PFS), the primary endpoint, vs. placebo plus Tarceva in patients with high c-MET-expressing NSCLC (12.4 vs. 6.4 weeks, p=0.0547). Roche's Genentech Inc. unit did not say whether the endpoint was met. MetMab plus Tarceva also improved overall survival vs. placebo plus Tarceva in patients with high c-MET expression (7.7 vs. 7.4 months, p=0.1113). The double-blind, international trial enrolled 128 patients. Data were presented at the European Society for Medical Oncology meeting in Milan. ...